Application of a high-level peracetic acid disinfection protocol to re-process antibiotic disinfected skin allografts.
Skin allografts, derived from cadaveric donors, are widely used for the treatment of burns and ulcers. Prior to use in clinical situations, these allografts are disinfected using a cocktail of antibiotics and then cryopreserved. Unfortunately, this antibiotic disinfection procedure fails to decontaminate a significant proportion and these contaminated grafts can not be used clinically. We have investigated whether it is possible to apply a second, more potent disinfection procedure to these contaminated grafts and effectively to re-process them for clinical use. Cadaveric skin grafts, treated with antibiotics and cryopreserved, were thawed and a peracetic acid (PAA) disinfection protocol applied. The grafts were then preserved in a high concentration of glycerol or propylene glycol, and properties thought to be essential for successful clinical performance assessed. The cytotoxicity of the grafts was assessed using both extract and contact assays; damage to the skin collagen was assessed using a collagenase susceptibility assay and the capacity of the grafts to elicit an inflammatory response in vitro was assessed by quantifying the production of the pro-inflammatory cytokine TNF-alpha by human peripheral blood mononuclear phagocytes. PAA disinfection, in conjunction with either glycerol or propylene glycol preservation, did not render the grafts cytotoxic, pro-inflammatory, or increase their susceptibility to collagenase digestion. The rates of penetration of glycerol and propylene glycol into the re-processed skin were comparable to those of fresh skin. This study has demonstrated that PAA disinfection combined with immersion in high concentrations of either glycerol or propylene glycol was an effective method for re-processing contaminated skin allografts, and may justify their clinical use.
Lomas
R J
RJ
National Blood Service Tissue Services R&D, Sheffield Blood Centre, Longley Lane, Sheffield S5 7JN, UK. richard.lomas@nbs.nhs.uk
Huang
Q
Q
Pegg
D E
DE
Kearney
J N
JN
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002102:Cadaver; D004058:Diffusion; D004202:Disinfectants / Q000494:pharmacology; D004203:Disinfection / Q000379:methods*; D005990:Glycerol / Q000737:chemistry; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D066298:In Vitro Techniques; D010463:Peracetic Acid / Q000494:pharmacology*; D019946:Propylene Glycol / Q000737:chemistry; D012867:Skin / Q000737:chemistry / Q000187:drug effects* / Q000382:microbiology* / Q000473:pathology; D016038:Skin Transplantation / Q000379:methods*; D014021:Tissue Preservation / Q000379:methods*; D014184:Transplantation, Homologous; D014867:Water / Q000737:chemistry
D000900:Anti-Bacterial Agents; D004202:Disinfectants; D014867:Water; D019946:Propylene Glycol; D010463:Peracetic Acid; D005990:Glycerol